Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Solid Biosciences (SLDB) Research & Development (2017 - 2024)

Solid Biosciences' Research & Development history spans 8 years, with the latest figure at $30.8 million for Q4 2024.

  • For Q4 2024, Research & Development rose 99.12% year-over-year to $30.8 million; the TTM value through Dec 2024 reached $96.4 million, up 25.95%, while the annual FY2024 figure was $96.4 million, 25.95% up from the prior year.
  • Research & Development for Q4 2024 was $30.8 million at Solid Biosciences, up from $27.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $30.8 million in Q4 2024 and bottomed at $13.4 million in Q2 2020.
  • The 5-year median for Research & Development is $17.8 million (2023), against an average of $18.8 million.
  • The largest annual shift saw Research & Development tumbled 41.91% in 2020 before it soared 99.12% in 2024.
  • A 5-year view of Research & Development shows it stood at $15.7 million in 2020, then decreased by 7.17% to $14.6 million in 2021, then soared by 45.87% to $21.3 million in 2022, then fell by 27.42% to $15.5 million in 2023, then skyrocketed by 99.12% to $30.8 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Research & Development are $30.8 million (Q4 2024), $27.3 million (Q3 2024), and $19.5 million (Q2 2024).